Panel Discussion: Detecting & Tracking Acquired Resistance Mutations to Expedite Clinical Decision-Making

• Establishing monitoring intervals frequent enough to catch resistance emergence before clinical progression
• Distinguishing true resistance signal from clonal noise to avoid switching therapy on a false trigger
• Building switch criteria into protocols so molecular progression is an actionable endpoint, not an observation

Speakers:

Hugh Wang

Director - Bioinformatics

Summit Plc

I-Ming Wang

Director - Translational Oncology

Pfizer